PHAXIAM Therapeutics Management

Management criteria checks 2/4

PHAXIAM Therapeutics' CEO is Thibaut Fayet, appointed in Jun 2023, has a tenure of 1.42 years. total yearly compensation is €391.73K, comprised of 34.5% salary and 65.5% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth €8.72K. The average tenure of the management team and the board of directors is 1.4 years and 11.5 years respectively.

Key information

Thibaut Fayet

Chief executive officer

€391.7k

Total compensation

CEO salary percentage	34.5%
CEO tenure	1.4yrs
CEO ownership	0.05%
Management average tenure	1.4yrs
Board average tenure	11.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Thibaut Fayet's remuneration changed compared to PHAXIAM Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€22m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€392k	€135k	-€23m

Compensation vs Market: Thibaut's total compensation ($USD413.43K) is about average for companies of similar size in the UK market ($USD359.47K).

Compensation vs Earnings: Insufficient data to compare Thibaut's compensation with company performance.

CEO

Thibaut Fayet (56 yo)

1.4yrs

Tenure

€391,725

Compensation

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thibaut Fayet	Chief Executive Officer	1.4yrs	€391.73k	0.055% € 8.7k
Jérôme Bailly	Deputy CEO	4.8yrs	€262.41k	0.0038% € 601.8
Frédéric Mathat	Chief Financial Officer	less than a year	no data	no data
Cindy Fevre	Chief Scientific Officer	1.8yrs	no data	no data
Naomi Eichenbaum	Director Investor Relations	no data	no data	no data
Pascal Birman	Chief Medical Officer	1.4yrs	no data	no data
Philip Lorenzi	Consultant & Member of Scientific Board	no data	no data	no data
Eric Raymond	Consultant & Member of Scientific Board	no data	no data	no data
Bridget Bax	Consultant & Member of Scientific Board	no data	no data	no data
Arthur Frankel	Consultant & Member of Scientific Board	no data	no data	no data
Kurt Gunter	Consultant & Member of Scientific Board	no data	no data	no data

1.4yrs

Average Tenure

56yo

Average Age

Experienced Management: 0QSS's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Philip Lorenzi	Consultant & Member of Scientific Board	14.8yrs	no data	no data
Eric Raymond	Consultant & Member of Scientific Board	15.1yrs	no data	no data
Bridget Bax	Consultant & Member of Scientific Board	12.8yrs	no data	no data
Arthur Frankel	Consultant & Member of Scientific Board	12.8yrs	no data	no data
Kurt Gunter	Consultant & Member of Scientific Board	12.8yrs	no data	no data
Philippe Archinard	Independent Director	11.5yrs	€68.00k	0.010% € 1.6k
Gil Beyen	Vice Chairman	11.5yrs	€1.00m	0.0048% € 769.0
Hilde Windels	Independent Director	10.2yrs	€56.75k	no data
Didier Hoch	Chairman of the Board	1.4yrs	€153.18k	no data
Leila Nicolas	Representative Director	1.4yrs	€26.25k	no data
Robert Sebbag	Independent Director	1.4yrs	€21.75k	no data
Valerie Faillat	Independent Director	less than a year	no data	no data

11.5yrs

Average Tenure

65yo

Average Age

Experienced Board: 0QSS's board of directors are seasoned and experienced ( 11.5 years average tenure).

PHAXIAM Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

No longer forecast to breakeven

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.70

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.80

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €8.07

New 90-day high: €6.55

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age